- Home
- / CURE Pharmaceutical
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
CURE Pharmaceutical financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$2.3
2024-10-29
Market Capitalization
$104.7 M
2024-10-29
Revenue
$4.3 M
FY, 2023
CreditSafe Score
?
Score changed on Jun 11, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 84.2K | 180.4K | 583.9K | 623.0K | 2.1M | 6.6M | 4.9M | 4.3M |
| Cost of goods sold | 153.3K | 180.6K | 279.9K | 231.0K | 1.1M | 2.2M | 1.6M | 1.2M |
| Gross profit | (69.2K) | (225.0) | 304.0K | 392.0K | 975.0K | 4.4M | 3.3M | 3.1M |
| Gross profit margin, % | -82.2% | -0.1% | 52.1% | 62.9% | 47.5% | 68.2% | 71.5% | |
| General and administrative expense | 3.1M | 5.9M | 6.5M | 10.1M | 11.4M | 18.9M | 11.7M | 9.1M |
| Operating expense total | 3.9M | 7.3M | 7.9M | 14.1M | 19.9M | 19.5M | 21.6M | 8.6M |
| Depreciation and amortization | 577.0K | |||||||
| EBIT | (3.9M) | (7.3M) | (7.6M) | (13.7M) | (19.0M) | (15.1M) | (18.3M) | (5.5M) |
| EBIT margin, % | -4664.9% | -4069.8% | -1294.3% | -2197.8% | -924.3% | -373.2% | -126.7% | |
| Interest income | 437.0 | 6.0 | 577.4K | 57.0K | 37.0K | 62.0K | 51.0K | 52.0K |
| Interest expense | 4.1M | 44.0K | 44.0K | |||||
| Pre tax profit | (4.2M) | (8.2M) | (10.4M) | (21.4M) | (30.6M) | (13.2M) | (18.5M) | (3.4M) |
| Income tax expense | 42.0K | (3.0K) | ||||||
| Net Income | (4.2M) | (8.1M) | (10.4M) | (21.4M) | (30.6M) | (13.2M) | (25.5M) | (3.4M) |